Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.

@article{Hudelist2007IntratumoralIP,
  title={Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.},
  author={Gernot Hudelist and Teresa M. U. Wagner and Marsha Rich Rosner and Anneliese Fink-Retter and Daphne Gschwantler-Kaulich and Klaus Czerwenka and Regina Kroiss and Muy-Kheng Maria Tea and Kerstin Pischinger and Wolfgang J. K{\"o}stler and Johannes Attems and Ruth Mueller and Claudia Blaukopf and Ernst Kubista and Markus Hengstschl{\"a}ger and Christian F. Singer},
  journal={Endocrine-related cancer},
  year={2007},
  volume={14 4},
  pages={
          1053-62
        },
  url={https://api.semanticscholar.org/CorpusID:25757934}
}
The increased intratumoral IGF-I protein expression in BRCA mutation carriers suggests an involvement of the IGF-i/IGF-IR axis in the biological behavior of breast cancers in this population and could define a potential therapeutic target.
View on PubMed
erc.bioscientifica.com
51 Citations
Highly Influential Citations
3
Background Citations
27

Figures and Tables from this paper

51 Citations

BRCA1 regulates insulin-like growth factor 1 receptor levels in ovarian cancer

It is demonstrated that IGF1R expression is increased in non-BRCA1-mutated ovarian cancer when compared with adjacent normal tissue, and IGF 1R levels are additionally significantly elevated in BRCA 1 inactivation ovarian cancer (B RCA1 mutation or hypermethylated BrcA1 promoter).

BRCA1 is Expressed in Uterine Serous Carcinoma (USC) and Controls Insulin-Like Growth Factor I Receptor (IGF-IR) Gene Expression in USC Cell Lines

Findings suggest a possible biological link between the BRCA1 and the IGF-I signaling pathways in USC and the clinical implications of this association need to be explored.

Comprehensive Proteomic Profiling–derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas

A well-applicable and accurate tool to predict which breast cancer patients may have an underlying BRCA germline mutation, largely consisting of immunohistochemical markers independent of clinical characteristics is presented.

Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation

The role of IGF1R in stem cell maintenance and lineage differentiation and how these cell fate influences may alter the differentiation potential and cellular composition of breast tumors are discussed.

BRCA1: An Endocrine and Metabolic Regulator

The present review article dissects the emerging role of BRCA1 as an important regulator of various endocrine and metabolic axes and identifies complex interactions between the insulin/insulin-like growth factor-1 (IGF1) signaling axis and BRCa1.

Elucidating the novel BRCA1 function as a non-genomic metabolic restraint in ER-positive breast cancer cell lines

A novel, non-genomic role for BRCA1 is characterized in restraining metabolic activity and IGF-I anabolic actions in breast cancer cells, with demonstrated downregulation of a phosphorylated and inactive form of acetyl CoA Carboxylase-α (ACCA), with a concomitant increase in fatty acid synthase (FASN) abundance.

IGF and Insulin Receptor Signaling in Breast Cancer

A better understanding of IGF system signal diversification in breast cancer has important implications for cancer prevention measures, which should include control of insulin resistance and associated hyperinsulinemia.

The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers

There was a lack of association of the KL-VS Klotho variant with either breast or ovarian cancer risk in BRCA1 and BRC a2 mutation carriers, and when carriers of the 6174delT mutation were excluded.

BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site

Findings suggest that BRCA1 defectiveness keeps turning on IGF-1/PI3K/AKT signaling, which significantly contributes to increase cell survival and proliferation.

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

It is hypothesized that IGF-1R inhibition might sensitize HR proficient cancers to Poly ADP ribose polymerase (PARP) inhibitors and Targeting both PARP and IGF- 1R might increase the clinical efficacy in HR deficient patients and increase the population of patients who may benefit from PARP inhibitors.
...

45 References

BRCA1 mutations in primary breast and ovarian carcinomas.

Results suggest that mutation of BRCA1 may not be critical in the development of the majority of breast and ovarian cancers that arise in the absence of a mutant germline allele.

Functional and Physical Interactions between BRCA1 and p53 in Transcriptional Regulation of the IGF-IR Gene

The data suggest that the transcriptional activity of BRCA1 depends on the cellular status of p53, and inability of mutant tumor suppressors to repress IGF-IR gene expression may result in increased IGF-ir levels and IGF binding, leading to a reduction in apoptosis and enhanced survival capacity of malignant cells.

Insulin-Like Growth Factor (IGF)-System mRNA Quantities in Normal and Tumor Breast Tissue of Women with Sporadic and Familial Breast Cancer Risk

It is shown that mRNA expression levels of IGF-system components in the breast are generally higher in normal tissue compared with tumor tissue, and higher in tissue from women with a family history of breast cancer.

Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families

It is suggested that lack of the IGF1 19-repeat allele modifies IGF-1 levels, breast volume and possibly early-onset breast cancer risk after hormone exposure in young high-risk women.

IGF-I in human breast cancer: low differentiation stage is associated with decreased IGF-I content.

IGF-I is associated with the more-differentiated type of epithelial cells and that increasing dedifferentiation goes along with decreased IGF-I content, which indicates a lower degree of malignancy than the lack of IGF- I.

BRCA1–Sp1 interactions in transcriptional regulation of the IGF‐IR gene

Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer

It is concluded that IGF-1R expression is not a major predictor of the clinical efficacy of trastuzumab-based treatment in patients with Her-2/neu- overexpressing metastatic breast cancer.

Insulin-like growth factors and breast cancer risk in Chinese women.

It is confirmed that high circulating levels of IGF-I are associated with elevated risk of breast cancer and that IGFBP-3 was positively associated with breast cancer risk in Chinese women.

The localization of the insulin‐like growth factor receptor 1 (IGFR‐1) in benign and malignant breast tissue

It is concluded that IGFR‐1 immunoreactivity is found in the majority of breast carcinomas, where it correlates most closely with oestrogen receptor status.

The insulin-like growth factor system in advanced breast cancer.